Pneumococcal disease describes a group of illnesses caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This bacterial pathogen, which affects both children and adults, is a major cause of death and illness worldwide. In fact, according to the World Health Organization (WHO), pneumococcal disease is the number one vaccine-preventable cause of death in children younger than 5 years of age worldwide.
Vaccines are an important part of routine healthcare for adults, seniors and women who are pregnant.
A study presented today (6 September 2016) at this year's European Respiratory Society International Congress in London, UK shows that adults admitted to hospital during school holidays are 38% more likely to have pneumococcal community-acquired pneumonia (CAP) than those admitted during term time.
Most people recoil at the thought of ingesting E. coli. But what if the headline-grabbing bacteria could be used to fight disease?
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Scientists from the University of Leicester have for the first time created a detailed image of a toxin - called pneumolysin - associated with deadly infections such as bacterial pneumonia, meningitis and septicaemia.
The American College of Physicians (ACP) was awarded a $1,002,884 Cooperative Agreement from the Centers for Disease Control and Prevention (CDC) to increase immunization rates in the United States.
The pneumococcal vaccine recommended for young children not only prevents illness and death, but also has dramatically reduced severe antibiotic-resistant infections, suggests nationwide research being presented at IDWeek 2014.
Influenza vaccination coverage estimates show an encouraging upward trend overall, but coverage among healthy 18 to 64 year-olds has yet to top 40 percent, according to new data announced at a news conference held today by the National Foundation for Infectious Diseases.
A survey of serogroup 6 Streptococcus pneumoniae isolates from children in China has identified no antibiotic-resistant clones, leading the authors to speculate that the isolates may be under antibiotic selective pressure.
Researchers report that the incidence of Streptococcus pneumoniae infection has fallen significantly in the USA in the past decade but describe a “concerning trend” whereby the baseline health status of those with serious pneumococcal disease has worsened.
The recently published National Immunization Survey (NIS) conducted by the CDC, shows that the majority of infants in the US were vaccinated against potentially serious diseases in 2013. Fewer than 1% of children were unvaccinated in 2013.
Canadian scientists have reported details of an outbreak of serotype 12F invasive pneumococcal disease that occurred in Winnipeg between 2009 and 2011 and predominantly affected people who were homeless and/or engaged in illegal drug use.
Children with chronic or immunocompromising medical conditions continue to be at increased risk for developing pneumococcal disease in the current era of universal immunisation, US researchers report.
Hospital patients with pneumococcal community-acquired pneumonia have worse outcomes if they are current smokers than if they are non- or ex-smokers, results of a large observational study suggest.
Swedish researchers studying Streptococcus pneumoniae have discovered “hypervirulent” mutant forms of the bacteria that are selected for because they are more resistant to clearance by macrophages.
The incidence of invasive pneumococcal disease in Taiwan has decreased significantly in recent years, study findings indicate.
In collaboration with the National Minority AIDS Council, Walgreens is furthering its commitment to improve HIV treatment outcomes for African Americans living with HIV by deepening pharmacists' training and expanding access to the pneumococcal vaccination specifically indicated for persons living with HIV as incidents of flu and pneumonia rise.
Children hospitalized for pneumonia have similar outcomes, including length of stay and costs, regardless of whether they are treated with "big gun" antibiotics such as ceftriaxone or cefotaxime or more narrowly focused antibiotics such as ampicillin or penicillin, according to a Vanderbilt study published in Pediatrics.
Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has initiated a Phase 1 study of GEN-004, an investigational vaccine candidate for pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. GEN-004 is the first vaccine candidate designed to prevent infections caused by all strains of pneumococcus through a novel T cell-mediated mechanism of action.
During Antibiotic Awareness Week (18-24 November) NPS MedicineWise is urging health professionals to use vaccinations as one important way to limit Australia’s use of antibiotics.